ImmunoPrecise Antibodies to Participate at H.C. Wainwright’s 27th Annual Global Investment Conference in New York

On September 2, 2025 ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), reported that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025 (Press release, ImmunoPrecise Antibodies, SEP 2, 2025, View Source [SID1234655643]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

Event Details:

•
Conference: 27th Annual H.C. Wainwright Global Investment Conference
•
Date: September 8-10th, 2025
Investors interested in scheduling a meeting with the IPA management team should contact their H.C. Wainwright representative or email [email protected]

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!